Payment overview · 2025
General Payments
$116.09
6 reported records · 5 companies
Healthcare provider profile · identity verified
Robert M Rose, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BEVERLY HILLS, CA · NPI 1396717450
Verified facts
What the public records show
CMS Open Payments records show Robert M Rose, M.D. received $116.09 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.81 | 30.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.30 | 20.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.15 | 19.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.95 | 16.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.88 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.09 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 584 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 87 |
| Losartan Potassium | Losartan Potassium | 248 | 70 |
| Potassium Chloride | Potassium Chloride | 231 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 54 |
| Eliquis | Apixaban | 193 | 47 |
| Carvedilol | Carvedilol | 190 | 51 |
| Furosemide | Furosemide | 165 | 58 |
| Simvastatin | Simvastatin | 152 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 30 |
| Lorazepam | Lorazepam | 118 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 27 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Lisinopril | Lisinopril | 103 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 27 |
| Gabapentin | Gabapentin | 95 | 23 |
| Synthroid | Levothyroxine Sodium | 90 | 17 |
| Allopurinol | Allopurinol | 87 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 15 |
| Famotidine | Famotidine | 81 | 20 |
| Atenolol | Atenolol | 80 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 76 | 21 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Spironolactone | Spironolactone | 68 | 19 |
| Omeprazole | Omeprazole | 66 | 22 |
| Trazodone Hcl | Trazodone Hcl | 62 | 11 |
| Finasteride | Finasteride | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 16 |
| Flecainide Acetate | Flecainide Acetate | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 46 | 11 |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Azithromycin | Azithromycin | 45 | 36 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | 11 |
| Klor-Con 10 | Potassium Chloride | 31 | 11 |
| Temazepam | Temazepam | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Repatha Pushtronex | Evolocumab | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Ramipril | Ramipril | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.09 · 6 records | Abbott Laboratories | AVEIR, CAMZYOS, GALLANT, MOUNJARO, REPATHA, VYNDAQEL, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error